Holappa Mervi, Vapaatalo Heikki, Vaajanen Anu
BioMediTech, University of Tampere, Tampere, Finland.
Medical Faculty, Department of Pharmacology, University of Helsinki, 00014 Helsinki, Finland.
Open Ophthalmol J. 2017 Jun 19;11:122-142. doi: 10.2174/1874364101711010122. eCollection 2017.
The renin-angiotensin system (RAS), that is known for its role in the regulation of blood pressure as well as in fluid and electrolyte homeostasis, comprises dozens of angiotensin peptides and peptidases and at least six receptors. Six central components constitute the two main axes of the RAS cascade. Angiotensin (1-7), an angiotensin converting enzyme 2 and Mas receptor axis (ACE2-Ang(1-7)-MasR) counterbalances the harmful effects of the angiotensin II, angiotensin converting enzyme 1 and angiotensin II type 1 receptor axis (ACE1-AngII-AT1R) Whereas systemic RAS is an important factor in blood pressure regulation, tissue-specific regulatory system, responsible for long term regional changes, that has been found in various organs. In other words, RAS is not only endocrine but also complicated autocrine system. The human eye has its own intraocular RAS that is present in the structures involved in aqueous humor dynamics. Local RAS may thus be a target in the development of new anti-glaucomatous drugs. In this review, we first describe the systemic RAS cascade and then the local ocular RAS especially in the anterior part of the eye.
肾素-血管紧张素系统(RAS)以其在血压调节以及体液和电解质稳态中的作用而闻名,它由数十种血管紧张素肽和肽酶以及至少六种受体组成。六个核心成分构成了RAS级联反应的两个主要轴。血管紧张素(1-7)、血管紧张素转换酶2和Mas受体轴(ACE2-Ang(1-7)-MasR)可抵消血管紧张素II、血管紧张素转换酶1和血管紧张素II 1型受体轴(ACE1-AngII-AT1R)的有害作用。虽然全身RAS是血压调节的重要因素,但在各个器官中也发现了负责长期区域变化的组织特异性调节系统。换句话说,RAS不仅是内分泌系统,也是复杂的自分泌系统。人眼有其自身的眼内RAS,存在于参与房水动力学的结构中。因此,局部RAS可能是新型抗青光眼药物开发的靶点。在这篇综述中,我们首先描述全身RAS级联反应,然后描述局部眼内RAS,特别是在眼球前部。